BioWorld

Jan. 3, 2002

View Archived Issues

Myogen Adds $14M To Series D To Support Late-Stage Products

Read More

Analysis Of Gene Expression In Human Eyeballs Reveals Never- Seen Inherited Genetic Mutants

Read More

Other News To Note

Read More

Correction

Read More

ImClone Suffers Erbitux Setback, Says It Won t Need New Trials

Analysts say the FDA s failure to accept ImClone Systems Inc. s rolling biologics license application for Erbitux in irinotecan-refractory colorectal cancer is expected to delay market launch by about six months. Read More